Fisetin: The Senolytic Hype vs the (Mostly Missing) Human Evidence

By Erin Rose · Updated July 18, 2026 · Methodology

Educational overview — not medical advice. Fisetin has no established RDA or upper limit, and the one completed human efficacy trial found no benefit over placebo. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

As an Amazon Associate we earn from qualifying purchases. On best fisetin, products are ranked by disclosed actual fisetin mg, absorption technology, and cost per actual mg — not by commissions.

Start here

What fisetin is, and the three tiers of evidence

Fisetin is a flavonoid found in small amounts in strawberries, apples, persimmons, and other fruits and vegetables. It's not an essential nutrient — there's no deficiency state, no RDA, and no government-set upper limit — so any claimed benefit of supplementing has to stand on its own evidence, not on "correcting a shortfall." Fisetin is marketed almost entirely on one word: senolytic, meaning it selectively clears senescent cells, the "zombie cells" that accumulate with age and secrete inflammatory factors (the senescence-associated secretory phenotype, or SASP). That idea comes almost entirely from one foundational study. Yousefzadeh 2018 screened 10 flavonoids for senolytic activity in mice and found fisetin was the most potent: intermittent treatment reduced senescence markers across multiple tissues in old and progeroid mice, and chronic late-life treatment in wild-type mice suppressed age-related pathology and extended both median and maximum lifespan. That same paper also tested fisetin on human adipose-tissue explants — donated human tissue kept alive in a dish, not a person taking a pill — and found reduced senescence markers there too. It's the reason fisetin is interesting at all, and it's also, without exception, preclinical data.

From there, the evidence sorts into two more tiers, both thinner than most buyers assume. Human cell-culture work (Mullen 2023) found fisetin dose-dependently reduced senescence markers in cultured human stem cells — stronger mechanistic support than mouse-only data, but still a dish, not a living person. And human clinical evidence — the only tier that can test a real outcome in real people — is the thinnest of all: a safety/pharmacokinetics trial, a trial-design paper for an unreported COVID study, a tiny uncontrolled self-dosing cohort, and exactly one completed, randomized, placebo-controlled efficacy trial. That one trial (ROPE, knee osteoarthritis) used the actual mouse-derived dose and found no benefit. See the full tiered breakdown on the evidence page.

Does it work? (the honest short version)

Not shown in humans yet — and the field didn't skip the step that would prove it, that step just came back null. Mayo Clinic's senolytics group runs several registered human fisetin trials that use the identical weight-based math from the mouse studies: roughly 20mg per kilogram of body weight, pulsed over 2-3 consecutive days per cycle, repeated in cycles weeks apart. For a 70kg adult that's approximately 1,400mg on a dosing day — far above what any retail bottle sells. Of the registered trials (AFFIRM and AFFIRM-LITE for frailty, COVID-FIS and COVFIS-HOME for COVID-19 complications, a chronic-kidney-disease trial, a peripheral-artery-disease trial, and ROPE for knee osteoarthritis), only ROPE has reported results as of this evidence pack's date. The result: no significant benefit on pain, function, or cartilage health vs placebo, with no significant safety concerns either. That's a materially different evidence state than "nobody has looked yet" — it's the one time the actual protocol was tested end-to-end, and it didn't clear the bar. See the full breakdown on the joint-health page.

The buying and safety problem

Unlike some ingredients in this category, fisetin doesn't have a documented purity-fraud scandal, and every product tracked here discloses its actual fisetin mg on the label — so a cost-per-mg comparison is honest and mechanically possible. The real buying problem is absorption: fisetin, like quercetin, is poorly absorbed orally and rapidly metabolized, with animal pharmacokinetic data reporting oral bioavailability around 8-32% and free plasma fisetin often undetectable within minutes. Only one delivery technology has human pharmacokinetic data behind it — a fenugreek-galactomannan hybrid-hydrogel formulation that improved absorption by roughly 27x in a small crossover trial (Krishnakumar 2022) — and the one retail product using that exact technology delivers only a small fraction of the dose tested in that trial. See the full ranking, including that specific tradeoff, on best fisetin. On safety: no significant signal has emerged across the human data — the ROPE trial reported 185 total adverse events (mostly minor: joint pain, nausea, headache, dry mouth) with no significant difference between fisetin and placebo groups, and the Krishnakumar PK study reported no significant adverse events at a single 1000mg dose. But no human trial has tested continuous DAILY dosing at retail-style amounts (100-500mg/day, indefinitely) for safety over any extended period — every trial that reported safety data used short pulsed cycles, not the daily-forever pattern retail products are sold for. As a flavonoid at high doses, fisetin has theoretical relevance to CYP450 enzyme interactions and platelet/coagulation pathways; anyone on anticoagulants, antiplatelet drugs, or chemotherapy should have a clinician review before use. There is no pregnancy or breastfeeding safety data at all.

Frequently asked questions

Related guides

• NMN — another longevity-marketed ingredient where a rigorous meta-analysis found a null result the marketing skips past
• Spermidine — a mouse-autophagy mechanism paired with a null primary endpoint in the one confirmatory human trial
• Urolithin A — a replicated human muscle-endurance signal, but 5 of 7 trials are funded by the ingredient's own maker
• CoQ10 — another mitochondrial-adjacent supplement with its own absorption-form distinction

Sources